World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 2504921

Number of visits today: 235

Number of downloads: 1686840

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Cheng P, Chen C, Yu M, Lin C, Lin C, Peng C, Tseng K, Lo C, Tseng I, Liu C. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. Journal of Microbiology, Immunology and Infection 2021;54:588-95. [DOI: 10.1016/j.jmii.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]

For:

Cheng P, Chen C, Yu M, Lin C, Lin C, Peng C, Tseng K, Lo C, Tseng I, Liu C. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. Journal of Microbiology, Immunology and Infection 2021;54:588-95. [DOI: 10.1016/j.jmii.2020.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]

Number	Citing Articles
1	Liu C, Liu C, Su T, Tseng T, Chen P, Kao J. Sofosbuvir/velpatasvir or glecaprevir/pibrentasvir for treating patients with hepatitis C virus reinfection following direct‐acting antiviral‐induced sustained virologic response. Adv in Digestive Medicine. [DOI: 10.1002/aid2.13302] [Reference Citation Analysis]
2	Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]